ORYZON Announces Journal Publication of Final Phase IIa REimagine Results with Vafidemstat
Oryzon Genomics announced the publication of final Phase IIa REIMAGINE study results, demonstrating the safety and efficacy of vafidemstat...
Benitec Biopharma’s BB-301 Study at MDA Conference
Benitec Biopharma announced interim clinical study updates for the first three subjects in its Phase 1b/2a trial of BB-301,...
Next-Gen Nectin-4 Targeting ADC Shows Promise in Phase 1 Study
Corbus Pharmaceuticals announced positive data from its US and UK Phase 1 dose escalation study of CRB-701, a next-generation...
Medicus Pharma Announces SKNJC-003 Phase 2 Nodular BCC Study Update
Medicus Pharma Ltd. (NASDAQ: MDCX) announced that its Phase 2 clinical trial (SKNJCT-003) for D-MNA, a treatment for basal...
StemSpine® Procedure Significantly Reduces Opioid Use in Chronic Lower Back Pain Patients
Creative Medical Technology Holdings (CELZ) announced positive mid-term results from its StemSpine pilot study using AlloStem cells to treat...
Cabometyx® & Opdivo® in Kidney Cancer: 5-Year CheckMate -9ER Results
Final results from the phase 3 CheckMate-9ER trial show that cabozantinib (CABOMETYX) combined with nivolumab (Opdivo) continues to demonstrate...
Relativity-098 Trial Update: BMS Provides Insights
Bristol Myers Squibb announced that the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for adjuvant treatment of...
Virpax & US Army Show Positive Probudur™ Results in Combat Care Study
Virpax Pharmaceuticals announced positive results from a U.S. Army Institute of Surgical Research (USAISR) study on Probudur™, a non-addictive...
ImmunityBio Anktiva® for BCG-Unresponsive Bladder Cancer: MHRA Accepts Marketing Authorization Application
ImmunityBio announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has accepted its marketing authorization application for...
Pfizer Talzenna & Xtandi Improve Survival in mCRPC
Pfizer announced positive Phase 3 TALAPRO-2 trial results for TALZENNA (talazoparib) combined with XTANDI (enzalutamide) in treating metastatic castration-resistant...